Patients Treated With Acoramidis Do Not Require Concomitant Tafamidis To Further Increase Serum TTR Levels

Acoramidis therapy significantly increases serum transthyretin (sTTR) levels in participants with TTR amyloid cardiomyopathy (ATTR-CM), compared with tafamidis plus placebo, according to a study being presented at ACC.25.

In this study, researchers analyzed the efficacy of tafamidis when administered concomitantly with acoramidis in increasing sTTR levels in patients from the ATTRibute-CM study. Patients were randomized in 2:1 fashion to receive either acoramidis or placebo. After 12 months, the study population could initiate concomitant tafamidis treatment, with sTTR levels monitored over a duration of 30 months.

The investigators noted that at month 12, the mean (SEM) changes from baseline in sTTR levels were as follows: acoramidis all, 7.9 (0.31) mg/dL and placebo all, −0.6 (0.33) mg/dL. Furthermore, at month 30, the mean (SEM) changes from baseline in sTTR levels were as follows: acoramidis only, 9.1 (0.38) mg/dL; placebo+ tafamidis, 6.4 (1.24) mg/dL; and acoramidis+ tafamidis, 8.9 (0.79) mg/dL. In the placebo-only group, researchers observed a mild decrease in sTTR levels after 30 months. Overall, acoramidis therapy was well tolerated across all groups.

Source

Maurer M, Cappelli F, Fontana M, et al. In participants treated with acoramidis, addition of concomitant tafamidis did not further increase serum TTR levels. Abstract presented at: American College of Cardiology 2025; March 29-31, Chicago, IL.